Ganesh has over 20 years of experience advancing innovative therapeutics across immunology, oncology, and rare diseases, from first-in-human through late-stage development. He has a strong track record of leading high-performing, clinical and cross-functional teams and delivering integrated clinical development strategies that combine clinical execution, translational medicine, and clinical pharmacology across multiple modalities, including small molecules, antibodies, antibody-drug conjugates, antisense oligonucleotides, and cell therapies. He has led and contributed to over 15 clinical programs, including trial design, dose and regimen optimization, biomarker integration, indication prioritization, go/no-go decisions, and engagement with global regulatory agencies. He has built strong relationships with key opinion leaders, medical advisory boards, and academic collaborators to inform development strategy and ensure scientific and clinical rigor.
Most recently, he served as Vice President and Head of Early Clinical Development at Astria Therapeutics, where he led scientific strategy and execution across immunologic and allergic disease programs and was a member of the senior leadership team, contributing to portfolio prioritization and investment decisions. Previously, he held leadership roles at Takeda, AstraZeneca, and Pfizer, contributing to the advancement of multiple development programs.
Ganesh holds a Master’s degree in drug design and development from M.S. University, Baroda, India, and a Ph.D. in clinical pharmacology from the University of Cincinnati.
